{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:44:41Z","timestamp":1789764281568,"version":"4.0.1"},"reference-count":62,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2020,6,5]]},"DOI":"10.3233\/jhd-200397","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T13:30:43Z","timestamp":1589290243000},"page":"107-113","source":"Crossref","is-referenced-by-count":38,"title":["Irritability in Huntington\u2019s Disease"],"prefix":"10.1177","volume":"9","author":[{"given":"Nicholas E.","family":"Karagas","sequence":"first","affiliation":[{"name":"McGovern Medical School at The University of Texas Health Sciences Center (UTHealth), Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Pessoa","family":"Rocha","sequence":"additional","affiliation":[{"name":"The Mitchell Center for Alzheimer\u2019s Disease and Related Brain Disorders, McGovern Medical School at UTHealth, Houston, TX, USA"},{"name":"HDSA Center of Excellence at UTHealth, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin Furr","family":"Stimming","sequence":"additional","affiliation":[{"name":"HDSA Center of Excellence at UTHealth, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"1","key":"10.3233\/JHD-200397_ref1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s disease: A clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur J Neurol"},{"issue":"10","key":"10.3233\/JHD-200397_ref2","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington\u2019s disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.3233\/JHD-200397_ref3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-71779-1_1","article-title":"Clinical features of Huntington\u2019s disease","author":"Ghosh","year":"1049","journal-title":"Adv Exp Med Biol"},{"key":"10.3233\/JHD-200397_ref4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.parkreldis.2016.02.008","article-title":"Neuropsychiatric symptoms are very common in premanifest and early stage Huntington\u2019s Disease","volume":"25","author":"Martinez-Horta","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"10.3233\/JHD-200397_ref5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","article-title":"Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data","volume":"8","author":"Tabrizi","year":"2009","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.3233\/JHD-200397_ref6","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/jnnp.71.3.310","article-title":"Neuropsychiatric aspects of Huntington\u2019s disease","volume":"71","author":"Paulsen","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.3233\/JHD-200397_ref7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1176\/jnp.23.4.jnp399","article-title":"Discriminant analysis of Beck Depression Inventory and Hamilton Rating Scale for Depression in Huntington\u2019s disease","volume":"23","author":"Rickards","year":"2011","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"4","key":"10.3233\/JHD-200397_ref8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1590\/s1980-5764-2016dn1004002","article-title":"Revisiting the neuropsychiatry of Huntington\u2019s disease","volume":"10","author":"Teixeira","year":"2016","journal-title":"Dement Neuropsychol"},{"issue":"7","key":"10.3233\/JHD-200397_ref9","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jaac.2016.04.014","article-title":"The status of irritability in psychiatry: A conceptual and quantitative review","volume":"55","author":"Vidal-Ribas","year":"2016","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.3233\/JHD-200397_ref10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.psychres.2007.03.002","article-title":"The Irritability Questionnaire: A new scale for the measurement of irritability","volume":"159","author":"Craig","year":"2008","journal-title":"Psychiatry Res"},{"key":"10.3233\/JHD-200397_ref11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cortex.2019.06.012","article-title":"Validity of irritability in Huntington\u2019s disease: A scoping review","volume":"120","author":"Simpson","year":"2019","journal-title":"Cortex"},{"key":"10.3233\/JHD-200397_ref12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/med\/9780199929146.003.0003","volume-title":"Neuropsychiatry and neuropsychology","author":"Craufurd","year":"2014"},{"key":"10.3233\/JHD-200397_ref13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.7916\/D8FJ2FD3","article-title":"The many facets of unawareness in huntington disease","volume":"4","author":"McCusker","year":"2014","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"5","key":"10.3233\/JHD-200397_ref14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11940-010-0088-3","article-title":"Treatment of irritability in Huntington\u2019s disease","volume":"12","author":"van Duijn","year":"2010","journal-title":"Curr Treat Options Neurol"},{"issue":"4","key":"10.3233\/JHD-200397_ref15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp.65.4.467","article-title":"Crime in Huntington\u2019s disease: A study of registered offences among patients, relatives, and controls","volume":"65","author":"Jensen","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.3233\/JHD-200397_ref16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/jnp.2007.19.4.441","article-title":"Psychopathology in verified Huntington\u2019s disease gene carriers","volume":"19","author":"van Duijn","year":"2007","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"1","key":"10.3233\/JHD-200397_ref17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1600-0447.1991.tb05511.x","article-title":"The clinical manifestation of mental disorder in Huntington\u2019s disease: A retrospective case record study of disease progression","volume":"83","author":"Pflanz","year":"1991","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"10.3233\/JHD-200397_ref18","first-page":"219","article-title":"Behavioral changes in Huntington Disease","volume":"14","author":"Craufurd","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"issue":"1","key":"10.3233\/JHD-200397_ref19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1176\/appi.neuropsych.11030057","article-title":"Longitudinal evaluation of neuropsychiatric symptoms in Huntington\u2019s disease","volume":"24","author":"Thompson","year":"2012","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"2-3","key":"10.3233\/JHD-200397_ref20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.psychres.2012.03.041","article-title":"Irritability in Huntington\u2019s disease","volume":"200","author":"Reedeker","year":"2012","journal-title":"Psychiatry Res"},{"issue":"12","key":"10.3233\/JHD-200397_ref21","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1136\/jnnp-2013-307343","article-title":"Neuropsychiatric symptoms in a European Huntington\u2019s disease cohort (REGISTRY)","volume":"85","author":"van Duijn","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.3233\/JHD-200397_ref22","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/mds.26675","article-title":"Rating scales for behavioral symptoms in Huntington\u2019s disease: Critique and recommendations","volume":"31","author":"Mestre","year":"2016","journal-title":"Mov Disord"},{"issue":"10","key":"10.3233\/JHD-200397_ref23","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1080\/01616412.2016.1214555","article-title":"Clinical and genetic characteristics in patients with Huntington\u2019s disease from China","volume":"38","author":"Yang","year":"2016","journal-title":"Neurol Res"},{"issue":"3","key":"10.3233\/JHD-200397_ref24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/s0165-1781(01)00257-8","article-title":"Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington\u2019s disease gene carriers","volume":"102","author":"Berrios","year":"2001","journal-title":"Psychiatry Res"},{"issue":"3","key":"10.3233\/JHD-200397_ref25","first-page":"192","article-title":"Longitudinal personality changes among presymptomatic Huntington disease gene carriers","volume":"15","author":"Kirkwood","year":"2002","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"issue":"2","key":"10.3233\/JHD-200397_ref26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.neuropsychologia.2009.10.016","article-title":"Irritability in pre-clinical Huntington\u2019s disease","volume":"48","author":"Kloppel","year":"2010","journal-title":"Neuropsychologia"},{"issue":"3","key":"10.3233\/JHD-200397_ref27","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1176\/jnp.17.3.378","article-title":"A comparison of self-report and caregiver assessment of depression, apathy, and irritability in Huntington\u2019s disease","volume":"17","author":"Chatterjee","year":"2005","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.3233\/JHD-200397_ref28","doi-asserted-by":"publisher","first-page":"RRN1259","DOI":"10.1371\/currents.RRN1259","article-title":"An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington\u2019s disease","volume":"3","author":"Groves","year":"2011","journal-title":"PLoS Curr"},{"key":"10.3233\/JHD-200397_ref29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/B978-0-12-801893-4.00011-0","article-title":"Medical treatment of behavioral manifestations of Huntington disease","volume":"144","author":"van Duijn","year":"2017","journal-title":"Handb Clin Neurol"},{"issue":"6","key":"10.3233\/JHD-200397_ref30","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1176\/appi.ps.53.6.703","article-title":"Psychiatric management of Huntington\u2019s disease in extended care settings","volume":"53","author":"Wood","year":"2002","journal-title":"Psychiatr Serv"},{"issue":"12","key":"10.3233\/JHD-200397_ref31","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1176\/appi.ajp.158.12.1966","article-title":"Successful multimodality treatment of severe behavioral disturbance in a patient with advanced Huntington\u2019s disease","volume":"158","author":"Blass","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.3233\/JHD-200397_ref32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/14737175.2016.1226134","article-title":"Antipsychotic drugs in Huntington\u2019s disease","volume":"17","author":"Unti","year":"2017","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"10.3233\/JHD-200397_ref33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1055\/s-2007-979558","article-title":"Long-term use of benzodiazepines: Tolerance, dependence and clinical problems in anxiety and mood disorders","volume":"29","author":"Michelini","year":"1996","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.3233\/JHD-200397_ref34","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1532-5415.2000.tb04729.x","article-title":"Benzodiazepines and the risk of falls in nursing home residents","volume":"48","author":"Ray","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JHD-200397_ref35","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3389\/fneur.2019.00710","article-title":"International guidelines for the treatment of Huntington\u2019s disease","volume":"10","author":"Bachoud-Levi","year":"2019","journal-title":"Front Neurol"},{"issue":"2","key":"10.3233\/JHD-200397_ref36","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s002130000575","article-title":"Fluoxetine in the treatment of Huntington\u2019s disease","volume":"153","author":"De Marchi","year":"2001","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.3233\/JHD-200397_ref37","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/mds.870120319","article-title":"A controlled trial of fluoxetine in nondepressed patients with Huntington\u2019s disease","volume":"12","author":"Como","year":"1997","journal-title":"Mov Disord"},{"issue":"3","key":"10.3233\/JHD-200397_ref38","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1176\/jnp.8.3.338","article-title":"Sertraline in the treatment of severe aggressiveness in Huntington\u2019s disease","volume":"8","author":"Ranen","year":"1996","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"1","key":"10.3233\/JHD-200397_ref39","first-page":"69","article-title":"Short-term effects of olanzapine in Huntington disease","volume":"14","author":"Squitieri","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"issue":"6","key":"10.3233\/JHD-200397_ref40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1034\/j.1600-0404.2002.01197.x","article-title":"Olanzapine in Huntington\u2019s disease","volume":"105","author":"Paleacu","year":"2002","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"10.3233\/JHD-200397_ref41","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1176\/appi.psy.47.1.70","article-title":"Quetiapine in the treatment of behavioral disturbances in patients with Huntington\u2019s disease","volume":"47","author":"Alpay","year":"2006","journal-title":"Psychosomatics"},{"issue":"16","key":"10.3233\/JHD-200397_ref42","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1002\/mds.22328","article-title":"Pisa syndrome and parkinsonism secondary to valproic acid in Huntington\u2019s disease","volume":"23","author":"Salazar","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JHD-200397_ref43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2377-6-11","article-title":"Dose-dependent improvement of myoclonic hyperkinesia due to valproic acid in eight Huntington\u2019s disease patients: A case series","volume":"6","author":"Saft","year":"2006","journal-title":"BMC Neurol"},{"issue":"13","key":"10.3233\/JHD-200397_ref44","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJM200009283431316","article-title":"Improvement of Huntington\u2019s disease with olanzapine and valproate","volume":"343","author":"Grove","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"10.3233\/JHD-200397_ref45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/0019-5545.105522","article-title":"Off label use of lithium in the treatment of Huntington\u2019s disease: A case series","volume":"55","author":"Danivas","year":"2013","journal-title":"Indian J Psychiatry"},{"issue":"6","key":"10.3233\/JHD-200397_ref46","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/JCP.0b013e31829c9748","article-title":"Lithium treatment in patients with Huntington disease and suicidal behavior","volume":"33","author":"Raja","year":"2013","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"10.3233\/JHD-200397_ref47","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1176\/ajp.151.7.1097a","article-title":"Beneficial effects of buspirone therapy in Huntington\u2019s disease","volume":"151","author":"Byrne","year":"1994","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.3233\/JHD-200397_ref48","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S0033-3182(93)71857-5","article-title":"Treatment of aggression in juvenile-onset Huntington\u2019s disease with buspirone","volume":"34","author":"Findling","year":"1993","journal-title":"Psychosomatics"},{"issue":"4","key":"10.3233\/JHD-200397_ref49","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0033-3182(97)71447-6","article-title":"Buspirone in the management of disruptive behaviors due to Huntington\u2019s disease and other neurological disorders","volume":"38","author":"Bhandary","year":"1997","journal-title":"Psychosomatics"},{"issue":"15","key":"10.3233\/JHD-200397_ref50","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1002\/mds.22809","article-title":"A pilot study using nabilone for symptomatic treatment in Huntington\u2019s disease","volume":"24","author":"Curtis","year":"2009","journal-title":"Mov Disord"},{"key":"10.3233\/JHD-200397_ref51","doi-asserted-by":"crossref","first-page":"A103","DOI":"10.1136\/jnnp-2016-314597.291","article-title":"M6 Nabilone in Huntington\u2019s disease: A case series of five patients","volume":"87","author":"Heim","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JHD-200397_ref52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/DNND.S83808","article-title":"Novel targets for Huntington\u2019s disease: Future prospects","volume":"6","author":"Mason","year":"2016","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"6106","key":"10.3233\/JHD-200397_ref53","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1126\/science.1226201","article-title":"Oxytocin\/vasopressin-related peptides have an ancient role in reproductive behavior","volume":"338","author":"Garrison","year":"2012","journal-title":"Science"},{"issue":"6","key":"10.3233\/JHD-200397_ref54","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/nan.12236","article-title":"Selective loss of oxytocin and vasopressin in the hypothalamus in early Huntington disease: A case study","volume":"41","author":"Gabery","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"12","key":"10.3233\/JHD-200397_ref55","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3109\/01612840.2015.1091869","article-title":"NueDexta: A treatment for pseudobulbar affect","volume":"36","author":"Roman","year":"2015","journal-title":"Issues Ment Health Nurs"},{"issue":"3","key":"10.3233\/JHD-200397_ref56","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s13311-016-0508-5","article-title":"Enhanced bulbar function in amyotrophic lateral sclerosis: The Nuedexta treatment trial","volume":"14","author":"Smith","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.3233\/JHD-200397_ref57","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40265-014-0328-z","article-title":"Dextromethorphan\/quinidine: A review of its use in adults with pseudobulbar affect","volume":"75","author":"Yang","year":"2015","journal-title":"Drugs"},{"issue":"8","key":"10.3233\/JHD-200397_ref58","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1212\/01.wnl.0000142042.50528.2f","article-title":"Treatment of pseudobulbar affect in ALS with dextromethorphan\/quinidine: A randomized trial","volume":"63","author":"Brooks","year":"2004","journal-title":"Neurology"},{"issue":"5","key":"10.3233\/JHD-200397_ref59","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ana.20828","article-title":"Randomized, controlled trial of dextromethorphan\/quinidine for pseudobulbar affect in multiple sclerosis","volume":"59","author":"Panitch","year":"2006","journal-title":"Ann Neurol"},{"key":"10.3233\/JHD-200397_ref60","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12883-016-0609-0","article-title":"PRISM II: An open-label study to assess effectiveness of dextromethorphan\/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury","volume":"16","author":"Hammond","year":"2016","journal-title":"BMC Neurol"},{"issue":"12","key":"10.3233\/JHD-200397_ref61","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jama.2015.10214","article-title":"Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: A randomized clinical trial","volume":"314","author":"Cummings","year":"2015","journal-title":"JAMA"},{"issue":"11","key":"10.3233\/JHD-200397_ref62","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1185\/03007995.2014.940040","article-title":"An open-label multicenter study to assess the safety of dextromethorphan\/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions","volume":"30","author":"Pattee","year":"2014","journal-title":"Curr Med Res Opin"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-200397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:51:02Z","timestamp":1777452662000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-200397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":62,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jhd-200397","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]}}}